Pharma Journalist -

Johnson & Johnson has secured U.S. Food and Drug Administration approval for RYBREVANT FASPRO™, marking a significant advance in the treatment of epidermal growth factor receptor…
Read More...

Beren Therapeutics P.B.C., the parent company of Mandos LLC, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to…
Read More...

Telix Pharmaceuticals has announced a strategic clinical collaboration with Varian, a Siemens Healthineers company and a global leader in radiation oncology, aimed at developing new…
Read More...

Zealand Pharma and OTR Therapeutics have entered into a multi-program strategic collaboration and licensing partnership aimed at discovering and developing a new generation of…
Read More...

Formation Bio and Lynk Pharmaceuticals have announced that Formation Bio has acquired worldwide rights—excluding Greater China—to LNK01006, a next-generation, central nervous system…
Read More...

China’s National Medical Products Administration (NMPA) has approved JASCAYD® (nerandomilast), marking the first new treatment for adults with progressive pulmonary fibrosis (PPF) in…
Read More...

Nanexa AB has entered into a new license and option agreement with Moderna Inc., marking a significant expansion of its long-acting injectable drug-delivery partnerships. The deal…
Read More...

China’s National Medical Products Administration (NMPA) has approved two innovative Sanofi therapies—Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired…
Read More...

Pfizer has released compelling new data from its Phase 3 HER2CLIMB-05 clinical trial, showing that the company’s tyrosine kinase inhibitor, TUKYSA® (tucatinib), significantly improved…
Read More...

Zydus Lifesciences has announced a major strategic partnership with Germany-based Formycon AG to develop and commercialize FYB206, a biosimilar version of the blockbuster immunotherapy…
Read More...